Compass Pathways PLC
Change company Symbol lookup
Select an option...
CMPS Compass Pathways PLC
NAPA Duckhorn Portfolio Inc
NDACU Nightdragon Acquisition Corp
EMPYF Empress Royalty Corp
CGC Canopy Growth Corp
FMCB Farmers & Merchants Bancorp
GM General Motors Co
CBMB CBM Bancorp Inc
SCHW Charles Schwab Corp
WSC Willscot Mobile Mini Holdings Corp
Go

Health Care : Biotechnology |
Based in United Kingdom
Company profile

COMPASS Pathways plc is a mental health care company, which is focused on developing treatments for people suffering with mental health challenges. The Company is focused on treatment-resistant depression (TRD). It is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$29.60
Day's Change
-2.35 (-7.36%)
Bid
--
Ask
--
B/A Size
--
Day's High
32.12
Day's Low
28.56
Volume
(Average)
Volume:
677,601

10-day average volume:
689,668
677,601

Company Profile

COMPASS Pathways plc is a mental health care company, which is focused on developing treatments for people suffering with mental health challenges. The Company is focused on treatment-resistant depression (TRD). It is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
4.37x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2021
Current Month
970.0K
Previous Month
1.1M
Percent of Float
2.43%
Days to Cover
0.5789 Days

Share Information

CMPS is in a share class of depositary receipt
Float
6.7M
Shares Outstanding
41.7M
Institutions Holding Shares
116
18.20%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.